We hypothesized that NY-ESO-1 and MAGE-A4 might function differently in the tumor microenvironment (TME) in highly aggressive sarcomas such as UPS, MFS, and MPNST tumors compared with mild progressive STSs. Here, MAGEA4 is linked to sarcoma.